This inventor holds 1 USPTO granted patent. Top assignee: Arcus Biosciences, Inc.. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: John Lippincott: Innovator in Cancer Treatment
Introduction
John Lippincott is a notable inventor based in San Diego, CA. He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic antibodies. His work focuses on enhancing the immune response against cancer and infectious diseases.
Latest Patents
Lippincott holds a patent for "Antibodies to TIGIT." This patent provides antibodies that specifically bind to TIGIT, a protein that plays a crucial role in regulating immune responses. The antibodies developed by Lippincott have the capacity for substantial activation of T cells and natural killer cells by inhibiting the binding of TIGIT to CD155. This innovation has potential applications in the treatment of cancer and infectious diseases.
Career Highlights
Lippincott is currently associated with Arcus Biosciences, Inc., a company dedicated to advancing cancer therapies. His work at Arcus has positioned him as a key player in the biotechnology sector, contributing to groundbreaking research and development.
Collaborations
Some of Lippincott's notable coworkers include Kelsey Sivick Gauthier and Nigel Pelham Clinton Walker. Their collaborative efforts in research have furthered the understanding and application of innovative therapies in the field.
Conclusion
John Lippincott's contributions to the development of antibodies targeting TIGIT represent a significant advancement in cancer treatment. His work continues to inspire innovation in the biotechnology industry.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile